Acquisitions1 Jun 2026, 09:00 am
Marksans Pharma to Acquire QliniQ B.V. for €7.5 Million
AI Summary
Marksans Pharma Ltd. will acquire 100% of Netherlands-based QliniQ B.V. for €7.5 million in cash. QliniQ, a pharmaceutical and medical device company, reported revenue of €9.35 million and a net profit of €1.01 million for FY2025. The acquisition aims to strengthen Marksans' presence in European markets by leveraging QliniQ's established sales, marketing, and distribution capabilities.
Key Highlights
- Marksans Pharma to acquire 100% of QliniQ B.V. for €7.5 million.
- QliniQ B.V. reported €9.35 million revenue and €1.01 million net profit in FY25.
- Acquisition strengthens Marksans' presence in European markets.
- QliniQ has established sales and distribution in the Netherlands.
- The acquisition is expected to be completed by June 15, 2026.
Price Impact
More from MARKSANS
More in Acquisitions